220 related articles for article (PubMed ID: 27153215)
1. A shot at AIDS.
Koff WC
Curr Opin Biotechnol; 2016 Dec; 42():147-151. PubMed ID: 27153215
[TBL] [Abstract][Full Text] [Related]
2. HIV/AIDS: vaccines and alternate strategies for treatment and prevention.
Voronin Y; Phogat S
Ann N Y Acad Sci; 2010 Sep; 1205 Suppl 1():E1-9. PubMed ID: 20860672
[TBL] [Abstract][Full Text] [Related]
3. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus.
Ahmad M; Ahmed OM; Schnepp B; Johnson PR
Annu Rev Virol; 2017 Sep; 4(1):491-510. PubMed ID: 28645240
[TBL] [Abstract][Full Text] [Related]
4. Antibodies in HIV-1 vaccine development and therapy.
Klein F; Mouquet H; Dosenovic P; Scheid JF; Scharf L; Nussenzweig MC
Science; 2013 Sep; 341(6151):1199-204. PubMed ID: 24031012
[TBL] [Abstract][Full Text] [Related]
5. HIV Vaccines: One Step Closer.
Low MSY; Tarlinton D
Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
7. Advances in HIV-1 Vaccine Development.
Gao Y; McKay PF; Mann JFS
Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
[TBL] [Abstract][Full Text] [Related]
8. The 2017 Keystone Symposium on HIV Vaccines.
Cottrell CA; Ward AB
Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733
[No Abstract] [Full Text] [Related]
9. Prospects for vaccine protection against HIV-1 infection and AIDS.
Letvin NL; Barouch DH; Montefiori DC
Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
[TBL] [Abstract][Full Text] [Related]
10. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
11. Use of broadly neutralizing antibodies for HIV-1 prevention.
Pegu A; Hessell AJ; Mascola JR; Haigwood NL
Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
[TBL] [Abstract][Full Text] [Related]
12. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
13. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
14. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
15. Current progress in the development of a prophylactic vaccine for HIV-1.
Gamble LJ; Matthews QL
Drug Des Devel Ther; 2010 Dec; 5():9-26. PubMed ID: 21267356
[TBL] [Abstract][Full Text] [Related]
16. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
17. Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.
Koff WC; Russell ND; Walport M; Feinberg MB; Shiver JW; Karim SA; Walker BD; McGlynn MG; Nweneka CV; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2():B204-8. PubMed ID: 23598483
[TBL] [Abstract][Full Text] [Related]
18. Closing the door to human immunodeficiency virus.
Kang Y; Guo J; Chen Z
Protein Cell; 2013 Feb; 4(2):86-102. PubMed ID: 23479426
[TBL] [Abstract][Full Text] [Related]
19. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
[TBL] [Abstract][Full Text] [Related]
20. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
